98%
921
2 minutes
20
Objective: Umbilical artery Doppler (UAD) velocimetry abnormalities are associated with increased neonatal morbidity and mortality. Currently, there are no risk stratification methods to assist in antepartum management such as timing of antenatal corticosteroids (ACS). Therefore, we sought to develop a model to predict risk of delivery within 7 days following diagnosis of abnormal UAD velocimetry in patients with fetal growth restriction (FGR).
Study Design: Retrospective single referral center study of liveborn singleton pregnancies complicated by FGR and ≥1 abnormal UAD velocimetry value (≥95th percentile for gestational age [GA]). We considered 17 variables and used backward stepwise logistic regression to create a multivariable model for the prediction of delivery within 7 days. We assessed model fit with calibration, discrimination, likelihood ratios, and area under the curve. Internal validation of the model was assessed by using the bootstrap method.
Results: Between 2008 and 2015, a total of 176 patients were eligible and included for model development. Median (range) GA at initial eligibility was 32.1 weeks (28.1-36.1 weeks) and from initial eligibility until delivery was 21 days (0-104 days). Fifty-two patients (30%) were delivered in the 7 days following inclusion. GA at first abnormal UAD, severity of first abnormal UAD, oligohydramnios, preeclampsia, and pre-pregnancy BMI were included in the model. The model had an area under the ROC curve of 0.94 (95% confidence interval [CI]: 0.90-0.98), sensitivity of 85%, and specificity of 91%. If the model alone were used for ACS timing, 85% of the cohort who delivered in the following week would have received ACS, and ACS would not have been given to 91% who delivered later. Internal validation yielded similar results with a mean area under the curve (95% CI) of 0.94 (0.88-0.98).
Conclusion: If validated externally, our model can be used to predict risk of delivery in patients with FGR and abnormal UAD velocimetry, potentially improving timing of ACS.
Key Points: · Risk of delivery in seven days can be predicted.. · Risk of delivery can inform corticosteroid timing.. · External validation can further develop a clinical aid..
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0041-1735222 | DOI Listing |
Am J Ophthalmol
September 2025
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address:
Objective: To examine the association between visual impairment (VI) and (1) homebound status, (2) presence of home hazards, and (3) utilization of home-based long-term services and supports (LTSS) among older adults.
Design: Longitudinal and cross-sectional analyses using National Health and Aging Trends Study (NHATS) data (2021-2023).
Subjects: 3,022 Medicare beneficiaries aged ≥71 years (mean age 78.
Int J Antimicrob Agents
September 2025
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China; National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, China. Electronic address:
Background: This study characterized the urinary pharmacokinetics and pharmacodynamics (PK/PD) of linezolid (LNZ) in critically ill patients with renal impairment and nosocomial multidrug-resistant Gram-positive urinary tract infections (UTIs). The aim was to address therapeutic challenges arising from limited treatment options and uncertain urinary excretion, to establish optimized dosing strategies.
Methods: A prospective observational study was conducted in ICU patients with renal impairment.
Int J Obstet Anesth
September 2025
Westmead Hospital Department of Anaesthesia and Perioperative Medicine, Westmead, Australia.
Background: Maternal cardiovascular disease (CVD) is a leading cause of maternal mortality. Data on anaesthetic management in patients with CVD is limited.
Methods: This ten-year retrospective cohort study of 508 pregnancies in women with CVD, stratified by modified World Health Organization (mWHO) risk category, compared lowrisk (mWHO I-II) (n = 323) and high-risk (mWHO II to III-IV) (n = 185) groups to a control obstetric population (n = 55,153).
Hum Reprod Update
September 2025
Women's Health Research Collaborative, New York, NY, USA.
Background: Reproductive-age women with intrauterine adhesions (IUAs) following uterine surgery may be asymptomatic or may experience light or absent menstruation, infertility, preterm delivery, and/or peripartum hemorrhage. Understanding procedure- and technique-specific risks and the available evidence on the impact of surgical adjuvants is essential to the design of future research.
Objective And Rationale: While many systematic reviews have been published, most deal with singular aspects of the problem.